mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2014-3-281-288mimmun-694Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВЛИЯНИЕ ИНТЕРФЕРОНОТЕРАПИИ НА ИММУНОФЕНОТИПИЧЕСКИЙ СПЕКТР И ЭНЗИМАТИЧЕСКУЮ АКТИВНОСТЬ ЛИМФОЦИТОВ ПЕРИФЕРИЧЕСКОЙ КРОВИ У БОЛЬНЫХ РАКОМ ПОЧКИEFFECTS OF INTERFERON THERAPY UPON IMMUNE MARKER PROFILE AND ENZYMATIC ACTIVITY IN PERIPHERAL BLOOD LYMPHOCYTES OF PATIENTS WITH RENAL CANCERКуртасоваЛ. М.KurtasovaL. M.

д.м.н., профессор кафедры клинической иммунологии ГБОУ ВПО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Министерства здравоохранения РФ

PhD, MD (Medicine), Professor,Clinical Immunology Department, Krasnoyarsk State V.F. Voyno-Yasenetsky Medical University, Ministry of Health Care of Russian Federation

office@aids.krsn.ruЗуковР. А.ZukovR. A.

к.м.н., доцент кафедры онкологии и лучевой терапии ГБОУ ВПО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Министерства здравоохранения РФ

PhD (Medicine), Assistant Professor, Department of Oncology and Radiation Therapy, Krasnoyarsk State V.F. Voyno-Yasenetsky Medical University, Ministry of Health Care of Russian Federation

ГБОУ ВПО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Министерства здравоохранения РФ, г. КрасноярскРоссияKrasnoyarsk State V.F. Voyno-Yasenetsky Medical University, Ministry of Health Care of Russian Federation, KrasnoyarskRussian Federation201401082014163281288Copyright © Куртасова Л.М., Зуков Р.А., 20142014Куртасова Л.М., Зуков Р.А.Kurtasova L.M., Zukov R.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/694

Под наблюдением находились 44 больных диссеминированным раком почки в периоде до лечения и после интерферонотерапии. Иммунофенотип лимфоцитов периферической крови определяли методом проточной цитофлуориметрии. Активность НАД(Ф)-зависимых дегидрогенез в лимфоцитах крови изучали биолюминесцентным методом. У больных раком почки после курса интерферонотерапии установлены изменения иммунофенотипического спектра и энзиматической активности лимфоцитов периферической крови.

We have observed forty-four patients with metastatic renal cancer before and after interferon therapy. Immune markers of of peripheral blood lymphocytes were determined by flow cytometry. Activity of NAD (P)-dependent dehydrogenase in blood lymphocytes was studied by means of bioluminescence technique. Changes of immune marker profiles and enzymatic activities of peripheral blood lymphocytes were found in patients with renal cancer after a course of interferon therapy.

рак почкииммунитетметаболизминтерферонотерапияrenal cancerimmunitymetabolisminterferon therapyReferencesDavydov M.I., Aksel` E.M. Zabolevaemost` zlokachestvennymi novoobrazovaniyami naseleniya Rossii i stran SNG v 2009 g. [The incidence of malignant tumors of Russian and CIS population in 2009]. Vestnik RONTS imeni N.N. Blokhina RAMN – Bulletin of the RCRC Named After N.N. Blokhin, 2011, vol. 24, no. 3 (suppl. 1), pp. 54-92.Davydov M.I., Aksel` E.M. Zabolevaemost` zlokachestvennymi novoobrazovaniyami naseleniya Rossii i stran SNG v 2009 g. [The incidence of malignant tumors of Russian and CIS population in 2009]. Vestnik RONTS imeni N.N. Blokhina RAMN – Bulletin of the RCRC Named After N.N. Blokhin, 2011, vol. 24, no. 3 (suppl. 1), pp. 54-92.Molchanov O.E., Karelin M.I. Immunologicheskiy monitoring bioterapii disseminirovannykh form pochechno-kletochnogo raka [Immunological monitoring of biotherapy of disseminated forms of renal cell carcinoma]. Onkourologiya – Oncourology, 2009. Vol. 4. pp. 13-18.Molchanov O.E., Karelin M.I. Immunologicheskiy monitoring bioterapii disseminirovannykh form pochechno-kletochnogo raka [Immunological monitoring of biotherapy of disseminated forms of renal cell carcinoma]. Onkourologiya – Oncourology, 2009. Vol. 4. pp. 13-18.Kurtasova L.M., Shkapova E.A., Savchenko A.A., Kryzhanovsky A.I., Zukov R.A., Rachkova N.V. Sposob otsenki chuvstvitel`nosti k interferonu u bol`nykh rakom pochki [A method of sensitivity evaluating to interferon in patients with renal cancer]. Pat. 2293988 RF N 2005 100610; Stated 11.01.05; Publ. 20.02.07. Bulletin of the Inventions. Utility models, 2007, no. 5. 5 p.Kurtasova L.M., Shkapova E.A., Savchenko A.A., Kryzhanovsky A.I., Zukov R.A., Rachkova N.V. Sposob otsenki chuvstvitel`nosti k interferonu u bol`nykh rakom pochki [A method of sensitivity evaluating to interferon in patients with renal cancer]. Pat. 2293988 RF N 2005 100610; Stated 11.01.05; Publ. 20.02.07. Bulletin of the Inventions. Utility models, 2007, no. 5. 5 p.Savchenko A.A., Suntsova L.N. Vysokochuvstvitel`noe opredelenie aktivnosti degidrogenaz v limfotsitakh perifericheskoy krovi biolyuminestsentnym metodom [Highly sensitive determination of dehydrogenase activity in lymphocytes of peripheral blood of bioluminescent method]. Laboratornoe delo –Laboratory Diagnostics, 1989, vol. 11, pp. 23-25.Savchenko A.A., Suntsova L.N. Vysokochuvstvitel`noe opredelenie aktivnosti degidrogenaz v limfotsitakh perifericheskoy krovi biolyuminestsentnym metodom [Highly sensitive determination of dehydrogenase activity in lymphocytes of peripheral blood of bioluminescent method]. Laboratornoe delo –Laboratory Diagnostics, 1989, vol. 11, pp. 23-25.Tyul`kova N.A., Antonova E.V. NAD(F) – reagent dlya biolyuminestsentnogo analiza. Preprint N 157 B Instituta Biofiziki SO AN SSSR [NAD (P) – a reagent for bioluminescent analysis. Preprint number 157 B of the Institute of Biophysics, Academy of Sciences of the USSR]. Krasnoyarsk, 1991. 18 p.Tyul`kova N.A., Antonova E.V. NAD(F) – reagent dlya biolyuminestsentnogo analiza. Preprint N 157 B Instituta Biofiziki SO AN SSSR [NAD (P) – a reagent for bioluminescent analysis. Preprint number 157 B of the Institute of Biophysics, Academy of Sciences of the USSR]. Krasnoyarsk, 1991. 18 p.Avnet S., Cenni E., Perut F., Granchi D., Brandi M.L., Giunti A., Baldini N. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma – induced angiogenesis. Int. J. Oncol., 2007, vol. 30, no. 2, pp. 469-476.Avnet S., Cenni E., Perut F., Granchi D., Brandi M.L., Giunti A., Baldini N. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma – induced angiogenesis. Int. J. Oncol., 2007, vol. 30, no. 2, pp. 469-476.B yusn A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 1968, vol. 21 (suppl. 97), pp. 77-89.B yusn A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 1968, vol. 21 (suppl. 97), pp. 77-89.Kelly J.D., Dai J., Eschwege P., Goldbreg J.S., Duggan B.P., Williamson K.E., Bander N.H., Nanus D.M. Downregulation of Bcl-2 sensitizes interferon-resistant renal cancer cells to Fas. Br. J. Cancer.,2004, vol. 91, no. 1, pp. 164-170.Kelly J.D., Dai J., Eschwege P., Goldbreg J.S., Duggan B.P., Williamson K.E., Bander N.H., Nanus D.M. Downregulation of Bcl-2 sensitizes interferon-resistant renal cancer cells to Fas. Br. J. Cancer.,2004, vol. 91, no. 1, pp. 164-170.Mailloux R.J., Harper M.E. Glucose regulates enzymatic sources of mitochondrial NADPH in skeletal muscle cells; a novel role for glucose-6-phosphate dehydrogenase. FASEB J., 2010, vol. 24, no. 7, pp. 2495- 2506.Mailloux R.J., Harper M.E. Glucose regulates enzymatic sources of mitochondrial NADPH in skeletal muscle cells; a novel role for glucose-6-phosphate dehydrogenase. FASEB J., 2010, vol. 24, no. 7, pp. 2495- 2506.Motzer R.J., Hudes G.R., Curti B.D., McDermott D.F., Escudier B.J., Negrier S., Duclos B., Moore L., O’Toole T., Boni J.P., Dutcher J.P. Phase I/II trial of temsirolimus combined with interferon-alpha for advanced renal cell carcinoma. J. Clin. Oncol., 2007, vol. 25, no. 25, pp. 3958-3964.Motzer R.J., Hudes G.R., Curti B.D., McDermott D.F., Escudier B.J., Negrier S., Duclos B., Moore L., O’Toole T., Boni J.P., Dutcher J.P. Phase I/II trial of temsirolimus combined with interferon-alpha for advanced renal cell carcinoma. J. Clin. Oncol., 2007, vol. 25, no. 25, pp. 3958-3964.Pallardo F.V., Markovic J., Garcia J.L., Vina J. Role of nurlear glutathione as a key regulator of cell proliferation. Mol. Aspects Med., 2009, vol. 30, no. 1-2, pp. 77-85.Pallardo F.V., Markovic J., Garcia J.L., Vina J. Role of nurlear glutathione as a key regulator of cell proliferation. Mol. Aspects Med., 2009, vol. 30, no. 1-2, pp. 77-85.Stanton R.C. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life, 2012,vol. 64, no. 5, pp. 362-369.Stanton R.C. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life, 2012,vol. 64, no. 5, pp. 362-369.Waggiallah H., Alzohairy M. The effect of oxidative stress on human red cells glutathione peroxidase, glutathioneraductase level, and prevalence of anemia among diabetics. N. Am. J. Sci., 2011, vol. 3, no. 7, pp. 344-347.Waggiallah H., Alzohairy M. The effect of oxidative stress on human red cells glutathione peroxidase, glutathioneraductase level, and prevalence of anemia among diabetics. N. Am. J. Sci., 2011, vol. 3, no. 7, pp. 344-347.

The authors declare that there are no conflicts of interest present.